| Levi Ammon Jensen, CPCI | |
|
757 S Main St, Springville, UT 84663-2452 | |
| (801) 491-2270 | |
| Not Available |
| Full Name | Levi Ammon Jensen |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 757 S Main St, Springville, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124339270 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 7390844-6009 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Levi Ammon Jensen, CPCI 757 S Main St, Springville, UT 84663-2452 Ph: (801) 491-2270 | Levi Ammon Jensen, CPCI 757 S Main St, Springville, UT 84663-2452 Ph: (801) 491-2270 |
News Archive
The millions of bacteria residing in the gut play a very important role in health and in disease. However, a constant issue has been the lack of understanding of the actual composition of the healthy human gut microbiome.
Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.
Data presented yesterday by researchers for Mallinckrodt plc, a leading specialty biopharmaceutical company, suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy.
Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.
University of Louisville researcher Jason Chesney, M.D., Ph.D., deputy director of the James Graham Brown Cancer Center, and a team of international scientists found that stage IIIb to IV melanoma patients treated with a modified cold sore (herpes) virus had improved survival.
› Verified 8 days ago
Leeanne Marie Davies, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1672 W 700 S, Springville, UT 84663 Phone: 801-489-9721 | |
Ms. Sara Joan Taylor, MSWI Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1672 W 700 S, Suite D, Springville, UT 84663 Phone: 801-489-9721 | |
Jordan Maready, CSWI Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 763 N 1650 W, Springville, UT 84663 Phone: 801-704-1339 | |
Jerilyn T Johnson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2452 W 500 S Unit 7, Springville, UT 84663 Phone: 801-557-3335 | |
Sandi Ness, CSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1220 N Main St, Springville, UT 84663 Phone: 801-358-4463 | |
Candela Anderson, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1672 W 700 S, Springville, UT 84663 Phone: 801-489-9721 | |
Jennifer Castillo Hurst, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1672 W 700 S Ste D, Springville, UT 84663 Phone: 801-489-9721 |